Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Obseva Sa Ordinary Shares (OBSV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 451,127
  • Shares Outstanding, K 36,440
  • Annual Sales, $ 16 K
  • Annual Income, $ -66,930 K
  • 36-Month Beta 1.75
  • Price/Sales 28,395.24
  • Price/Cash Flow N/A
  • Price/Book 2.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.47
  • Number of Estimates 5
  • High Estimate -0.44
  • Low Estimate -0.51
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +2.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.70 +1.92%
on 11/19/18
17.87 -33.24%
on 10/22/18
-4.54 (-27.57%)
since 10/19/18
3-Month
10.87 +9.75%
on 08/21/18
19.40 -38.51%
on 09/21/18
+1.01 (+9.25%)
since 08/20/18
52-Week
9.05 +31.82%
on 01/24/18
20.35 -41.38%
on 06/18/18
+1.18 (+10.98%)
since 11/20/17

Most Recent Stories

More News
ObsEva SA (OBSV) Reports Q3 Loss, Misses Revenue Estimates

ObsEva SA (OBSV) delivered earnings and revenue surprises of 8.70% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

OBSV : 11.93 (-3.63%)
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

- IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019

OBSV : 11.93 (-3.63%)
ObsEva Sees Hammer Chart Pattern: Time to Buy?

ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.

OBSV : 11.93 (-3.63%)
ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018

Geneva, Switzerland and Boston, MA -October 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics...

OBSV : 11.93 (-3.63%)
Report: Developing Opportunities within Just Energy Group, Tetra Technologies, Domtar, MacroGenics, ObsEva SA, and Magic Software Enterprises -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Just Energy Group, Inc....

MGNX : 16.71 (-1.01%)
MGIC : 7.96 (-1.24%)
OBSV : 11.93 (-3.63%)
UFS : 44.07 (-2.04%)
TTI : 2.45 (-4.67%)
JE : 3.94 (-0.76%)
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting

- Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART)

OBSV : 11.93 (-3.63%)
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018

EQNX::TICKER_START (:OBSV), EQNX::TICKER_END

OBSV : 11.93 (-3.63%)
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)

- Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment

OBSV : 11.93 (-3.63%)
ObsEva (OBSV) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in ObsEva SA (OBSV).

OBSV : 11.93 (-3.63%)
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain

- Linzagolix overall efficacy and safety maintained or improved at week 24

OBSV : 11.93 (-3.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade OBSV with:

Business Summary

ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland.

See More

Key Turning Points

2nd Resistance Point 13.47
1st Resistance Point 12.70
Last Price 11.93
1st Support Level 11.45
2nd Support Level 10.97

See More

52-Week High 20.35
Fibonacci 61.8% 16.03
Fibonacci 50% 14.70
Fibonacci 38.2% 13.37
Last Price 11.93
52-Week Low 9.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar